JP2016503655A - リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 - Google Patents

リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 Download PDF

Info

Publication number
JP2016503655A
JP2016503655A JP2015550820A JP2015550820A JP2016503655A JP 2016503655 A JP2016503655 A JP 2016503655A JP 2015550820 A JP2015550820 A JP 2015550820A JP 2015550820 A JP2015550820 A JP 2015550820A JP 2016503655 A JP2016503655 A JP 2016503655A
Authority
JP
Japan
Prior art keywords
sequence
listeria
polynucleotide
acta
residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015550820A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016503655A5 (enExample
Inventor
ラウア，ピーター，エム．
ハンソン，ウィリアム，ジー．
スコーブル，ジャスティン
レイ，リン レオン，メレディス
レイ，リン レオン，メレディス
ファッソ，マーセラ
ブロックステッド，ダーク
ドゥベンスキー，トーマス，ダブリュー．
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chinook Therapeutics Inc
Original Assignee
Chinook Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chinook Therapeutics Inc filed Critical Chinook Therapeutics Inc
Publication of JP2016503655A publication Critical patent/JP2016503655A/ja
Publication of JP2016503655A5 publication Critical patent/JP2016503655A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/036—Fusion polypeptide containing a localisation/targetting motif targeting to the medium outside of the cell, e.g. type III secretion
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Physics & Mathematics (AREA)
JP2015550820A 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用 Pending JP2016503655A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261746237P 2012-12-27 2012-12-27
US61/746,237 2012-12-27
US201361780744P 2013-03-13 2013-03-13
US61/780,744 2013-03-13
PCT/US2013/078119 WO2014106123A1 (en) 2012-12-27 2013-12-27 Signal peptide fusion partners facilitating listerial expression of antigenic sequences and methods of preparation and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018074066A Division JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Publications (2)

Publication Number Publication Date
JP2016503655A true JP2016503655A (ja) 2016-02-08
JP2016503655A5 JP2016503655A5 (enExample) 2017-02-16

Family

ID=51017446

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015550820A Pending JP2016503655A (ja) 2012-12-27 2013-12-27 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018074066A Expired - Fee Related JP6671408B2 (ja) 2012-12-27 2018-04-06 リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用

Country Status (12)

Country Link
US (2) US9663557B2 (enExample)
EP (1) EP2938627B1 (enExample)
JP (2) JP2016503655A (enExample)
KR (1) KR102160322B1 (enExample)
CN (1) CN104955835B (enExample)
AU (2) AU2013370210B2 (enExample)
BR (1) BR112015015076A2 (enExample)
CA (1) CA2888727A1 (enExample)
EA (1) EA201590397A8 (enExample)
MX (1) MX2015008329A (enExample)
SG (2) SG11201502792TA (enExample)
WO (1) WO2014106123A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2853269B1 (en) 2008-05-19 2019-05-01 Advaxis, Inc. Dual delivery system for heterologous antigens comprising a recombinant Listeria strain attenuated by mutation of dal/dat and deletion of ActA comprising a nucleic acid molecule encoding an listeriolysin O - prostate specific anigen fusion protein
US9650639B2 (en) 2008-05-19 2017-05-16 Advaxis, Inc. Dual delivery system for heterologous antigens
US9017660B2 (en) 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors
US10016617B2 (en) 2009-11-11 2018-07-10 The Trustees Of The University Of Pennsylvania Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers
EP2621527A4 (en) 2010-10-01 2015-12-09 Univ Pennsylvania USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE IMMUNITY IN PATIENTS WITH PARASITIC INFECTIONS
AU2012229218B2 (en) 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
EP3193921A4 (en) 2014-07-18 2018-04-25 Advaxis, Inc. Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
WO2016061115A1 (en) 2014-10-13 2016-04-21 Providence Health & Services-Oregon D/B/A Providence Portland Medical Center Bacterial vaccines deficient in the 2-c-methyl-d-erythritol-4-phosphate pathway and methods of preparation and use thereof
JP6895380B2 (ja) 2015-02-06 2021-06-30 ナショナル ユニバーシティ オブ シンガポール 治療免疫細胞の有効性を改良するための方法
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
US10105427B2 (en) * 2015-04-13 2018-10-23 Aduro Biotech, Inc. Epidermal growth factor receptor variant III-mesothelin fusions and methods of using the same
EP3283100A2 (en) 2015-04-13 2018-02-21 Aduro Biotech, Inc. Immunogenic fusion proteins for the treatment of cancer
EP3298031B1 (en) * 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
HRP20221263T1 (hr) * 2016-03-18 2023-03-03 Immune Sensor, Llc Ciklički di-nukleotidni spojevi i postupci uporabe
AU2017363278B2 (en) 2016-11-22 2022-10-27 National University Of Singapore Blockade of CD7 expression and chimeric antigen receptors for immunotherapy of T-cell malignancies
CA3071282A1 (en) 2017-08-10 2019-02-14 National University Of Singapore T cell receptor-deficient chimeric antigen receptor t-cells and methods of use thereof
SG11202002157TA (en) 2017-09-19 2020-04-29 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
JP7227237B2 (ja) 2017-10-10 2023-02-21 グリットストーン バイオ インコーポレイテッド ホットスポットを利用した新生抗原の特定
US11885815B2 (en) 2017-11-22 2024-01-30 Gritstone Bio, Inc. Reducing junction epitope presentation for neoantigens
EP3536706A1 (en) 2018-03-09 2019-09-11 BiOMVis Srl Fusion proteins for the outer membrane vesicle (omv) delivery of heterologous polypeptides and immunogenic compositions thereof
AU2019231783B2 (en) 2018-03-09 2023-11-16 Advaxis, Inc. Compositions and methods for evaluating attenuation and infectivity of Listeria strains
CN110408634B (zh) * 2018-04-27 2021-08-03 苏州若泰医药科技有限公司 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法
EP3785029A1 (en) 2018-04-27 2021-03-03 Advaxis, Inc. Compositions and methods for evaluating potency of listeria-based immunotherapeutics
SG11202010996QA (en) 2018-05-23 2020-12-30 Nat Univ Singapore Blockade of cd2 surface expression and expression of chimeric antigen receptors for immunotherapy of t-cell malignancies
EP3725371A1 (en) 2019-04-18 2020-10-21 BiOMVis Srl Method for the production of outer membrane vesicles and immunogenic compositions thereof
CN110499324A (zh) * 2019-09-02 2019-11-26 中生康元生物科技(北京)有限公司 一种用于鉴定肿瘤新抗原的细菌表达载体及筛选鉴定肿瘤新抗原的方法
BR112022026509A2 (pt) 2020-06-23 2023-03-07 Univ Colorado Regents Métodos para diagnosticar patógenos respiratórios e prever resultados relacionados à covid-19

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527240A (ja) * 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830702A (en) 1990-10-31 1998-11-03 The Trustees Of The University Of Pennsylvania Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
IT1262895B (it) 1992-03-02 1996-07-22 Proteina estratta da ceppi citotossici di helicobacter pylori, gene che la esprime, uso della proteina come vaccino o diagnostico.
US6379943B1 (en) 1999-03-05 2002-04-30 Merck & Co., Inc. High-efficiency Cre/loxp based system for construction of adenovirus vectors
US8114414B2 (en) 1994-11-08 2012-02-14 The Trustees Of The University Of Pennsylvania Compositions and methods for treatment of cervical cancer
US6051237A (en) 1994-11-08 2000-04-18 The Trustees Of The University Of Pennsylvania Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6099848A (en) 1997-11-18 2000-08-08 The Trustees Of The University Of Pennsylvania Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use
US6855320B2 (en) 2000-03-29 2005-02-15 The Trustees Of The University Of Pennsylvania Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity
JP2004500405A (ja) * 2000-03-29 2004-01-08 ザ　トラスティーズ　オブ　ザ　ユニバーシティー　オブ　ペンシルヴァニア 抗原の免疫原性を増強するための組成物および方法
CA2460014A1 (en) 2000-09-21 2002-03-28 The Regents Of The University Of California Spas-1 cancer antigen
AU2003259109A1 (en) 2002-07-12 2004-02-02 The Johns Hopkins University Mesothelin vaccines and model systems
EP1682173A4 (en) 2003-10-15 2007-10-31 Medimmune Inc EPHA2 VACCINE ON LISTERIA BASE
US7842289B2 (en) * 2003-12-24 2010-11-30 Aduro Biotech Recombinant nucleic acid molecules, expression cassettes, and bacteria, and methods of use thereof
US7858097B2 (en) * 2004-08-13 2010-12-28 The Trustees Of The University Of Pennsylvania Antibiotic resistance free Listeria strains and methods for constructing and using same
WO2007117371A2 (en) 2006-03-01 2007-10-18 Anza Therapeutics, Inc. Engineered listeria and methods of use thereof
US7935804B2 (en) 2006-03-01 2011-05-03 Aduro Biotech Engineered Listeria and methods of use thereof
EP1991263B8 (en) 2006-03-01 2015-02-25 Aduro Biotech Engineered listeria and methods of use thereof
WO2008008311A1 (en) 2006-07-10 2008-01-17 The Trustees Of The University Of Pennsylvania Methods for administering tumor vaccines
CN102076843A (zh) * 2008-05-19 2011-05-25 艾杜罗生物科技公司 包含prfa*突变体李斯特菌的组合物及其使用方法
GB201010389D0 (en) 2010-06-21 2010-08-04 Ist Superiore Sanita Antibody derivatives
DK2640842T3 (en) 2010-11-17 2018-08-13 Aduro Biotech Inc Methods and compositions for inducing an immune response to EGFRVIII
AU2012229218B2 (en) * 2011-03-11 2017-03-02 Advaxis, Inc. Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527240A (ja) * 2002-05-29 2005-09-15 ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 弱毒リステリア種とこれを使用する方法
JP2010534058A (ja) * 2007-04-16 2010-11-04 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルバニア 抗生物質耐性のないリステリア菌およびその構築および使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CANCER RESEARCH, vol. 64, no. 24, JPN6017042188, 2004, pages 8821 - 8825, ISSN: 0003886902 *
SCIENCE, vol. 290, JPN6017042189, 2000, pages 992 - 995, ISSN: 0003674817 *

Also Published As

Publication number Publication date
KR102160322B1 (ko) 2020-09-25
JP6671408B2 (ja) 2020-03-25
SG11201502792TA (en) 2015-05-28
HK1215260A1 (zh) 2016-08-19
US20170253637A1 (en) 2017-09-07
AU2013370210A1 (en) 2015-06-18
JP2018135355A (ja) 2018-08-30
EA201590397A1 (ru) 2016-02-29
EP2938627A4 (en) 2016-12-14
WO2014106123A8 (en) 2016-06-16
KR20150099738A (ko) 2015-09-01
EP2938627A1 (en) 2015-11-04
MX2015008329A (es) 2016-03-01
AU2018203555A1 (en) 2018-06-07
SG10201700916SA (en) 2017-03-30
US9663557B2 (en) 2017-05-30
EP2938627B1 (en) 2019-03-20
EA201590397A8 (ru) 2016-08-31
US20140186387A1 (en) 2014-07-03
WO2014106123A1 (en) 2014-07-03
CN104955835A (zh) 2015-09-30
CN104955835B (zh) 2020-04-17
BR112015015076A2 (pt) 2018-10-30
AU2013370210B2 (en) 2018-06-14
CA2888727A1 (en) 2014-07-03
AU2013370210A8 (en) 2016-06-23

Similar Documents

Publication Publication Date Title
JP6671408B2 (ja) リステリアの抗原配列の発現を容易にするシグナルペプチド融合パートナー、ならびにその調製方法およびその使用
JP5998370B2 (ja) Ｅｇｆｒｖｉｉｉに対する免疫応答を誘発する方法および組成物
US20120100170A1 (en) Compositions and methods for the treatment of hepatitis c
CN104838004A (zh) 兼性减毒细菌种类及其制备和使用方法
AU2013341242A1 (en) Facultatively attenuated bacterial species and methods of preparation and use thereof
TW201809274A (zh) 蛋白質表現強化子序列及其用途
HK1215260B (zh) 促进抗原序列的李斯特菌表达的信号肽融合配偶体以及其制备和使用方法
US20130323275A1 (en) Methods and compositions for inducing a t-cell response to plasmodium species
HK1190757B (en) Methods and compositions for inducing an immune response to egfrviii
HK1190757A (en) Methods and compositions for inducing an immune response to egfrviii

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160610

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161227

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171016

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171107

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180206

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180406

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20181002